is glp-1 an incretin Biology of Incretins: and GIP Those discontinuing GLP-1 medications rapidly

Tau, amyloid beta and deep brain stimulation: aiming to restore cognitive deficit in Alzheimers disease

The disease-related pathological changes and serum indicators in the CUMR and CURD models are highly similar to those in patients in the clinic, and therapeutic medicines can effectively improve brain function and behavior in these models

These findings suggest that GLP-1 receptor agonists may be an option worth considering for type 2 diabetes patients at risk of RVO, potentially contributing to favorable long-term ocular outcomes and reducing the burden of visual impairment in this population, the researchers concluded in their paper.

Track your response in a journal or app

Class B GPCRs are important therapeutic targets